{"id":"W4393184830","doi":"10.1182/bloodadvances.2023011030","title":"Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; Jewish General Hospital","funders":"National Cancer Institute; Incyte; BeiGene; Genentech; AstraZeneca; Celgene; Seagen; Gilead Sciences; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Brentuximab vedotin; Nivolumab; Lymphoma; Medicine; Oncology; Internal medicine; Refractory (planetary science); CD30; Immunotherapy; Biology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001798898,0.0005172861,0.0006988233,0.0002678365,0.0003069653,0.0002229566,0.0002412186,0.0002186463,0.0001648043],"category_scores_gemma":[0.0001697517,0.0004695314,0.00026734,0.0003640454,0.0003431567,0.0003219397,0.0001243734,0.0001847663,0.00008257829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004037895,"about_ca_system_score_gemma":0.001013989,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007292545,"about_ca_topic_score_gemma":0.00009553915,"domain_scores_codex":[0.9967878,0.00008307488,0.0005123494,0.00107368,0.0006555765,0.000887503],"domain_scores_gemma":[0.9983578,0.0004702641,0.0000983888,0.0004754836,0.0002253431,0.0003727607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01036507,0.01312332,0.01024208,0.01363756,0.001064165,0.01071221,0.006708355,0.0001376395,0.1432886,0.0007652604,0.01078532,0.7791703],"study_design_scores_gemma":[0.0747307,0.01090089,0.0004949537,0.001182117,0.001239232,0.02325162,0.004201563,0.02114423,0.06984528,0.001683342,0.7891541,0.00217201],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8689702,0.1163431,0.0003977707,0.0005714934,0.0006150985,0.001702207,0.0001472449,0.0003921711,0.01086074],"genre_scores_gemma":[0.9680662,0.00499023,0.002214341,0.0003022322,0.000475269,0.0002546945,0.0001035769,0.000172985,0.02342051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7783687,"threshold_uncertainty_score":0.9997756,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01127234975270641,"score_gpt":0.2798334425537646,"score_spread":0.2685610928010582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}